

**CSCO USCACA Session - " Translating Science into Medicine – Early Phase Cancer Drug Development of Immuno-oncology Combinations and Novel Targeted Agents"**

**Date: September 28<sup>th</sup>, 2017**

<b>Opening Remarks: Unleashing the full potential of Immuno-oncology Drugs</b>	2:30-2:40	CTEP/NCI GSK	Helen Chen Li Yan
Combination of Immuno-therapy with chemotherapy	2:40-2:52	Merck	Joe Eid (Global Medical Affairs Head, Oncology, Merck)
Combination of cancer immuno-therapy with MEKi in CRC and MOA	2:52-3:04	Genentech	Yunxia Zou Medical Director and Head of Clin Dev. of atezolizumab, Roche, China <i>(Bill Grossman)</i>
Combination of Immuno-therapy with anti-VEGF/VEGF <sub>i</sub> and other TKIs	3:04-3:16	Merck Serono	Zhen Su Global VP of Medical Affairs, Merck Serono
Combination of nivolumab with ipilimumab in solid tumors	3:16-3:28	BMS Oncology	Jie Chen (Oncology Disease Area Head, China) Sutinder Bindra (Country Medical Director)
B Cell Maturation Antigen – Antibody Drug Conjugate in Multiple Myeloma	3:28-3:40	GSK	Li Yan (VP & Head Unit Physician, GSK Oncology)
Discussion 1 & Q&A	3:40-3:50		Jay Mei
<b>China cancer drug R&amp;D Highlights (Jay Mei &amp; Dajun Yang + CSCO PI)</b>			
The Development of the First Oral MetAP2 inhibitor APL-1202 for the Treatment of Genito-Urinary Cancers	3:50-4:02	Asieris Pharmaceuticals	Kevin Pan, President and CEO
Exploring potential combinations of immuno-oncology for cancer treatment	4:02-4:14	Hengrui Pharma	Jessie Zou, VP Oncology
HER-2 Antibody-drug Conjugate	4:14-4:26	Chinese Academy of Medicine, Cancer Hospital	Prof. Binghe Xu Jianmin Fang
Lessons learned from developing the 3 <sup>rd</sup> Generation EGFR inhibitors in China	4:26-5:38	ACEA Pharma	Prof. Yi-long Wu Xiao Xu, President and CEO
Discussion 2 & Q&A	4:38-4:48		Dajun Yang
Panel discussion (Unmet medical needs and future opportunities in immunotherapy arena)	4:48-5:00		Zhimin Yang /Helen Chen / Li Yan&
Session Closure			Yi-long Wu